Quantum BioPharma Ltd (NASDAQ:QNTM) shares are rising Tuesday after the company announced positive clinical trial results for its unbuzzd dietary supplement.

placebo-controlled crossover design clinical trial (NCT06505239) of its dietary supplement product unbuzzd™, investigating its effects on alcohol intoxication and alcohol metabolism. Results of ...

placebo-controlled crossover design clinical trial (NCT06505239) of its dietary supplement product unbuzzd™, investigating its effects on alcohol intoxication and alcohol metabolism. Results of ...

Quantum BioPharma announced that it has completed a double-blind, randomized, placebo-controlled crossover design clinical trial of its dietary ...

BioPharma Ltd. (NASDAQ: QNTM) surged 95% following the announcement of positive results from its clinical trial for the dietary supplement unbuzzd™. The trial confirmed that unbuzzd™ significantly ...

placebo-controlled crossover design clinical trial (NCT06505239) of its dietary supplement product unbuzzd™, investigating its effects on alcohol intoxication and alcohol metabolism. Results of data ...